@article{94aaeb82bd33467997f2134e3ed8567b,
title = "COVID-19 and emerging viral infections: The case for interferon lambda",
abstract = "With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.",
author = "Ludmila Prokunina-Olsson and No{\'e}mie Alphonse and Dickenson, {Ruth E.} and Durbin, {Joan E.} and Glenn, {Jeffrey S.} and Rune Hartmann and Kotenko, {Sergei V.} and Lazear, {Helen M.} and O{\textquoteright}Brien, {Thomas R.} and Charlotte Odendall and Onabajo, {Olusegun O.} and Helen Piontkivska and Santer, {Deanna M.} and Reich, {Nancy C.} and Andreas Wack and Ivan Zanoni",
note = "Funding Information: L. Prokunina-Olsson, O.O. Onabajo, and T.R. O{\textquoteright}Brien are supported by the Intramural Research Program of the National Cancer Institute/National Institutes of Health. H.M. Lazear is supported by National Institutes of Health grant R01AI39512. H. Piontkivska is supported by National Institutes of Health grant R21AG064479-01 and a Brain Health Research Institute Pilot Award from Kent State University. C. Odendall is supported by a Sir Henry Dale Fellowship from the Royal Society and the Wellcome Trust (206200/Z/17/Z). A. Wack is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001206), the UK Medical Research Council (FC001206) and the Wellcome Trust (FC001206). R.E. Dickenson is supported by a studentship from the UK Medical Research Council. N. Alphonse is supported by a studentship from the King{\textquoteright}s College London/ Francis Crick Institute partnership. I. Zanoni is supported by National Institutes of Health grants 1R01 AI121066, 1R01DK115217, and NIAID-DAIT-NIHAI201700100. The content of this publication and the opinions expressed reflect those of the individual authors solely and do not necessarily reflect the views or policies of the US Department of Health and Human Services, the National Institutes of Health, or corresponding research institutes. Funding Information: We would like to acknowledge the input of other members of the interferon lambda community who participated in discussions on this topic: Evangelos Andreakos, Francine Baker, Connor Bamford, Raymond Donnelly, Darragh Duffy, Adriana Forero, Amariliz Rivera-Medina, Ram Savan, and Nikaia Smith. The Viewpoint was also inspired by the guest session on type III IFNs at the American Association of Immunologists 2020 meeting, which was canceled due to COVID-19; we appreciate the support for this session provided by the Interferon and Cytokine and Interferon Society. The figure was created using BioRender.com. L. Prokunina-Olsson, O.O. Onabajo, and T.R. O?Brien are supported by the Intramural Research Program of the National Cancer Institute/National Institutes of Health. H.M. Lazear is supported by National Institutes of Health grant R01AI39512. H. Piontkivska is supported by National Institutes of Health grant R21AG064479-01 and a Brain Health Research Institute Pilot Award from Kent State University. C. Odendall is supported by a Sir Henry Dale Fellowship from the Royal Society and the Wellcome Trust (206200/Z/17/Z). A. Wack is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001206), the UK Medical Research Council (FC001206) and the Wellcome Trust (FC001206). R.E. Dickenson is supported by a studentship from the UK Medical Research Council. N. Alphonse is supported by a studentship from the King?s College London/ Francis Crick Institute partnership. I. Zanoni is supported by National Institutes of Health grants 1R01 AI121066, 1R01DK115217, and NIAID-DAIT-NIHAI201700100. The content of this publication and the opinions expressed reflect those of the individual authors solely and do not necessarily reflect the views or policies of the US Department of Health and Human Services, the National Institutes of Health, or corresponding research institutes. Publisher Copyright: {\textcopyright} 2020 Prokunina-Olsson et al.",
year = "2020",
month = may,
day = "4",
doi = "10.1084/jem.20200653",
language = "English (US)",
volume = "217",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "5",
}